Medical research group Recardio has reportedly halted a trial of an experimental heart drug because of uncertainties surrounding the UK’s departure from the European Union. More: Recardio halts UK heart trial on Brexit uncertainty Source: News
read moreTwo talcum cases have ended in mistrials in recent weeks as juries failed to decide whether marketer Johnson & Johnson—and its storied baby powder—are responsible for plaintiffs’ cancers. More: With hung jury, second straight talcum case against Johnson & Johnson
read moreParatek Pharmaceuticals felt double the love from the FDA this week, as two of its antibiotics won back-to-back approvals—one for Paratek itself, and the other for deal partner Allergan’s dermatology buyer Almirall. More: 2 Paratek antibiotics win FDA nods, with
read moreRoche and Novartis are hoping to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing just that. More: Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
read moreMerck & Co. is out of stock and dealing with back orders of some of its Sinemet Parkinson’s disease drug products that won’t be resolved until next year. The issues have resulted from manufacturing problems at the CMO that produces the
read moreMylan is battling claims that it illegally boosted EpiPen sales, and plaintiffs say the company is engaged in legal skullduggery in the process. They say the generics maker is secretly urging vendors to withhold certain subpoenaed documents. More: Mylan secretly
read more© 1994 - 2026 B.M. Pharmaceuticals